📣 VC round data is live. Check it out!

Embecta Valuation Multiples

Discover revenue and EBITDA valuation multiples for Embecta and similar public comparables like KORU Medical Systems, Stille, Bastide Le Confort Médical, Paragon Care and more.

Embecta Overview

About Embecta

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.


Founded

2021

HQ

United States

Employees

1.9K

Financials (LTM)

Revenue: $1B
EBITDA: $361M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Embecta Financials

Embecta reported last 12-month revenue of $1B and EBITDA of $361M.

In the same LTM period, Embecta generated $640M in gross profit, $361M in EBITDA, and $87M in net income.

Revenue (LTM)


Embecta P&L

In the most recent fiscal year, Embecta reported revenue of $1B and EBITDA of $415M.

Embecta is profitable as of last fiscal year, with gross margin of 63%, EBITDA margin of 38%, and net margin of 9%.

See analyst estimates for Embecta
LTMLast FY202320242025202620272028
Revenue$1B$1B$1B$1B$1B
Gross Profit$640M$677M$746M$721M$660M
Gross Margin61%63%67%65%62%
EBITDA$361M$415M$232M$216M$295M
EBITDA Margin34%38%21%19%28%
EBIT Margin27%31%21%26%27%
Net Profit$87M$95M$72M$83M$92M
Net Margin8%9%6%7%9%
Net Debt—$1B———

Financial data powered by Morningstar, Inc.

Embecta Stock Performance

Embecta has current market cap of $199M, and enterprise value of $1B.

Market Cap Evolution


Embecta's stock price is $3.36.

Embecta share price decreased by 63.3% in the last 30 days, and by 68.1% in the last year.

Embecta has an EPS (earnings per share) of $1.61.

See more trading valuation data for Embecta
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$199M-7.7%-63.3%-67.3%-68.1%$1.61

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Embecta Valuation Multiples

Embecta trades at 1.3x EV/Revenue multiple, and 3.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Embecta

EV / Revenue (LTM)


Embecta Financial Valuation Multiples

As of May 12, 2026, Embecta has market cap of $199M and EV of $1B.

Embecta has a P/E ratio of 2.3x.

LTMLast FY202320242025202620272028
EV/Revenue1.3x1.3x1.2x1.2x1.3x
EV/EBITDA3.8x3.3x5.9x6.4x4.7x
EV/EBIT4.8x4.1x5.7x4.8x4.8x
EV/Gross Profit2.1x2.0x1.8x1.9x2.1x
P/E2.3x2.1x2.8x2.4x2.2x
EV/FCF—7.5x38.2x22.7x8.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Embecta Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Embecta Margins & Growth Rates

Embecta decreased revenue by 4% and EBITDA by 21% in the last fiscal year.

In the most recent fiscal year, Embecta reported gross margin of 63%, EBITDA margin of 38%, and net margin of 9%.

See estimated margins and future growth rates for Embecta

Embecta Margins

Last FY202420252026202720282029
Gross Margin63%65%62%59%
EBITDA Margin38%19%28%31%
EBIT Margin31%26%27%24%
Net Margin9%7%9%8%
FCF Margin17%5%15%11%

Embecta Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(4%)(1%)(4%)(2%)
Gross Profit Growth(10%)(3%)(8%)(7%)
EBITDA Growth(21%)(7%)37%10%
EBIT Growth(25%)20%(1%)(12%)
Net Profit Growth(14%)14%12%(6%)
FCF Growth(42%)69%170%(32%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Embecta Operational KPIs

Embecta's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.

Embecta's Rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Embecta's Rule of X is 25% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Embecta
LTMLast FY202320242025202620272028
Rule of 4035%29%———
Bessemer Rule of X36%25%———
Revenue per Employee—$0.6M———
Opex per Employee—$0.2M———
R&D Expenses to Revenue3%3%7%6%3%
Opex to Revenue—35%45%39%36%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Embecta Competitors

Embecta competitors include KORU Medical Systems, Stille, Bastide Le Confort Médical, Paragon Care, Quipt Home Medical, Medika, Mercator Medical, Microbot Medical, Standard Glass Lining and Prim.

Most Embecta public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
KORU Medical Systems4.4x4.1x274.6x183.1x
Stille3.6x3.4x17.9x16.1x
Bastide Le Confort Médical1.0x1.0x4.6x4.6x
Paragon Care0.2x0.2x7.0x6.1x
Quipt Home Medical—1.1x——
Medika0.2x—3.9x—
Mercator Medical0.7x—5.8x—
Microbot Medical3467.5x37.9x(4.7x)—

This data is available for Pro users. Sign up to see all Embecta competitors and their valuation data.

Start Free Trial

Embecta M&A Activity

Embecta has acquired 1 company to date.

Last acquisition by Embecta was on March 18th 2026. Embecta acquired Owen Mumford for $201M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Embecta

Owen Mumford
Description
Owen Mumford is a Woodstock-based manufacturer of medical devices for drug delivery and blood sampling. The company produces autoinjectors like Autopen and Unifine pen needles alongside lancets such as Auto-Lanc and Safe-T-Pro Plus. Owen Mumford supplies products to healthcare providers in over 100 countries, emphasizing user-friendly designs for diabetes management and diagnostics. Its portfolio includes the AmbiDexter straw pipette for precise fluid handling in labs.
HQ CountryUnited Kingdom
HQ City
Oxford
Deal Date18 Mar 2026
Valuation$201M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Embecta acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Embecta

When was Embecta founded?Embecta was founded in 2021.
Where is Embecta headquartered?Embecta is headquartered in United States.
How many employees does Embecta have?As of today, Embecta has over 1K employees.
Who is the CEO of Embecta?Embecta's CEO is Devdatt Kurdikar.
Is Embecta publicly listed?Yes, Embecta is a public company listed on Nasdaq.
What is the stock symbol of Embecta?Embecta trades under EMBC ticker.
When did Embecta go public?Embecta went public in 2022.
Who are competitors of Embecta?Embecta main competitors include KORU Medical Systems, Stille, Bastide Le Confort Médical, Paragon Care, Quipt Home Medical, Medika, Mercator Medical, Microbot Medical, Standard Glass Lining, Prim.
What is the current market cap of Embecta?Embecta's current market cap is $199M.
What is the current revenue of Embecta?Embecta's last 12 months revenue is $1B.
What is the current revenue growth of Embecta?Embecta revenue growth (NTM/LTM) is 1%.
What is the current EV/Revenue multiple of Embecta?Current revenue multiple of Embecta is 1.3x.
Is Embecta profitable?Yes, Embecta is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Embecta?Embecta's last 12 months EBITDA is $361M.
What is Embecta's EBITDA margin?Embecta's last 12 months EBITDA margin is 34%.
What is the current EV/EBITDA multiple of Embecta?Current EBITDA multiple of Embecta is 3.8x.
How many companies Embecta has acquired to date?As of May 2026, Embecta has acquired 1 company.
What was the largest acquisition by Embecta?$201M acquisition of Owen Mumford on 18th March 2026 was the largest M&A Embecta has done to date.
What companies Embecta acquired?Embecta acquired Owen Mumford.
In how many companies Embecta has invested to date?Embecta hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Embecta

Lists including Embecta

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial